NCT03146910 Swiss Primary Biliary Cholangitis Cohort Study
| NCT ID | NCT03146910 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Epatocentro Ticino |
| Condition | PBC |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2017-02-15 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2017-02-15 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.
Eligibility Criteria
Inclusion Criteria: * diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases). * Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included * Patients/subjects aged at least 18 years and living in Switzerland are included Exclusion Criteria: * N/A
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03146910 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PBC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03146910 currently recruiting?
Yes, NCT03146910 is actively recruiting participants. Contact the research team at andreas.cerny@hin.ch for enrollment information.
Where is the NCT03146910 trial being conducted?
This trial is being conducted at Lugano, Switzerland, Basel, Switzerland, Bern, Switzerland, Bülach, Switzerland and 9 additional locations.
Who is sponsoring the NCT03146910 clinical trial?
NCT03146910 is sponsored by Fondazione Epatocentro Ticino. The trial plans to enroll 500 participants.